Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 10/20 | 0.79 |
| ▸ | PIP4K2B | P78356 | 10/20 | 0.79 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.70 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.70 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.65 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.65 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.61 |
| ▸ | CDK7 | P50613 | 7/20 | 0.57 |
| ▸ | CCNH | P51946 | 7/20 | 0.57 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22595064 | 0.90 | PIP4K2A (0.64) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL20093343 | 0.89 | PIP4K2A (0.68) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL20093352 | 0.89 | PIP4K2A (0.68) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL18340746 | 0.86 | PIP4K2A (0.81) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL18340744 | 0.86 | PIP4K2A (0.81) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL29888600 | 0.86 | PIP4K2A (0.81) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL20093351 | 0.84 | PIP4K2A (0.83) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL20093341 | 0.83 | PIP4K2A (0.80) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL14979773 | 0.82 | MAPK8 (1.00) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 | |
| SCHEMBL29416038 | 0.82 | MAPK8 (1.00) | PIP4K2APIP4K2BMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315894-A9 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200338075-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338075-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDK3, CDK1, CDK14 | PIP4K2A 10/4885PIP4K2B 13/4885MAPK8 286/4885 |
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | CDK3, CDK1, CDK14 | PIP4K2A 10/4885PIP4K2B 13/4885MAPK8 286/4885 |
| US-20210315894-A9 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDK3, CDK1, CDK14 | PIP4K2A 10/4885PIP4K2B 13/4885MAPK8 286/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | PIP4K2A 6/4885PIP4K2B 8/4885MAPK8 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.